Pralatrexate: treatment of T-cell non-Hodgkin's lymphoma. - Wikidata - awgldk - TriplyDB

Pralatrexate: treatment of T-cell non-Hodgkin's lymphoma.

Pralatrexate: treatment of T-cell non-Hodgkin's lymphoma.

http://www.wikidata.org/entity/Q33404897

about

Pralatrexate: treatment of T-cell non-Hodgkin's lymphoma.

http://www.wikidata.org/entity/Q33404897

description

2013 nî lūn-bûn

@nan

2013 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Pralatrexate: treatment of T-cell non-Hodgkin's lymphoma.

@ast

Pralatrexate: treatment of T-cell non-Hodgkin's lymphoma.

@en

type

label

Pralatrexate: treatment of T-cell non-Hodgkin's lymphoma.

@ast

Pralatrexate: treatment of T-cell non-Hodgkin's lymphoma.

@en

prefLabel

Pralatrexate: treatment of T-cell non-Hodgkin's lymphoma.

@ast

Pralatrexate: treatment of T-cell non-Hodgkin's lymphoma.

@en

P1433

Q33404897-E56B0B6C-11F0-4E26-8861-3AB6C59DD987

P1476

Q33404897-82E33D25-135C-4E69-8093-EF2AE31641C7

P2093

Q33404897-09AB1BB8-E880-4DB9-A649-0C1648FC38D1

Q33404897-2E0E2D5A-D0EA-4323-B990-1DB97EC725EF

Q33404897-D3E36A2A-B7F1-47CB-BE49-DE5B40ACE3FD

P2860

Q33404897-00F4E073-77D5-46C2-8B84-4499E39A971B

Q33404897-0D7C2780-F26F-412F-A090-9F517918A824

Q33404897-21FAD46D-DD1E-4061-83CB-44D7D7D22570

Q33404897-2F2CA209-B407-4A91-AD45-54F1B96253E0

Q33404897-3AEBA92D-07EE-409B-9272-183AA3BBC93B

Q33404897-43136292-28DB-4A3B-95C5-87347EAD7BE8

Q33404897-56F12DF6-D1DB-47AD-AD9A-86EDE171A770

Q33404897-5B5AC4F5-7FE9-4C5C-8C90-A64E6F7B82D4

Q33404897-7991AAF2-5907-4C29-8356-8D4A3054FF93

Q33404897-7C6A21EB-0E49-4612-92E6-67F25091B15E

P304

Q33404897-EBFE94CD-82AB-463F-A407-B2EEC75B04AE

P31

Q33404897-0E90D01E-59CC-4318-8E81-FDD980B7A01D

P356

Q33404897-C319F36F-F7F4-4B95-B6E1-6080F019182D

P407

Q33404897-DA4250F2-ADF9-4E7C-ACA7-8BA03EAD5A7D

P433

Q33404897-EEDBF805-EFCD-4FD8-993D-58E8E93FC15D

P478

Q33404897-4FBC6A1F-9F1A-4563-B466-B914DDF1E38E

P577

Q33404897-DC4DFED0-959C-433B-A2BF-B6DDF8B53133

P698

Q33404897-E5B3690B-FB77-4632-B7E2-5D89B283F27B

P356

P1433

Future Oncology

P1476

Pralatrexate: treatment of T-cell non-Hodgkin's lymphoma.

@en

P2093

Francine Foss

http://www.w3.org/2001/XMLSchema#string

Lisa Barbarotta

http://www.w3.org/2001/XMLSchema#string

Terri Parker

http://www.w3.org/2001/XMLSchema#string

P2860

Peripheral T-cell non-Hodgkin's lymphoma

NKT cells mediate pulmonary inflammation and dysfunction in murine sickle cell disease through production of IFN-gamma and CXCR3 chemokines.

Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma.

Folotyn (pralatrexate injection) for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma: U.S. Food and Drug Administration drug approval summary.

Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study

Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma.

Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy.

Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma.

Pralatrexate is an effective treatment for relapsed or refractory transformed mycosis fungoides: a subgroup efficacy analysis from the PROPEL study.

Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study.

P304

21-29

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/FON.12.168

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P577

2013-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23252560

http://www.w3.org/2001/XMLSchema#string